ILLUCCIX (Telix Pharmaceuticals (ANZ) Pty Ltd)
Product name
ILLUCCIX
Date registered
Evaluation commenced
Decision date
Approval time
213 (255 working days)
Active ingredients
Glu-urea-Lys(ahx)-hbed-CC
Registration type
EOI
Indication
for the selection of patients with metastatic prostate cancer in whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.